Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on October 31, 2025. The report discloses significant changes to the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
- Director Resignation: Robert Ferrara resigned effective immediately from his positions as a Director, Lead Independent Director, and member of the Compensation and Audit Committees.
- Board Size Reduction: The Board reduced its size from six (6) to five (5) members following Mr. Ferrara's departure.
- Appointment: David Deming was appointed as the new Lead Independent Director.
- Reason for Departure: The resignation was not the result of any disagreement with the Company.
Outlook, Risks, and Management Commentary
Management confirmed that the Board currently has no vacancies following the reduction in size and the appointment of Mr. Deming. No specific guidance, risks, or contingencies regarding financial operations were disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of Robert Ferrara's resignation (October 31, 2025).
- Confirm the appointment of David Deming as Lead Independent Director.
- Note the reduction of the Board of Directors to five members.
- Review the attached press release (Exhibit 99.1) for additional details on the leadership transition.